Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial

作者：Lei Fan, Zhonghua Wang, Linxiaoxi Ma, Song‐Yang Wu, Jiong Wu, Ke‐Da Yu, Xin-Yi Sui, Ying Xu, Xiyu Liu, Li Chen, Wenjuan Zhang, Xi Jin, Qin Xiao, Ruohong Shui, Yi Xiao, Han Wang, Yun‐Song Yang, Xiaoyan Huang, A‐Yong Cao, Junjie Li, Gen‐Hong Di, Guang‐Yu Liu, Wen-Tao Yang, Xin Hu, Yan Xia, Qian-Nan Liang, Yi‐Zhou Jiang, Zhi‐Ming Shao · 发表于：The Lancet Oncology · 年份：2024 · DOI：10.1016/s1470-2045(23)00579-x · 被引用次数：71 · 研究领域：Breast Cancer Treatment Studies、Cancer Immunotherapy and Biomarkers、Advanced Breast Cancer Therapies